コンテンツへスキップ
Merck
  • Direct Contraction Force Measurements of Engineered Cardiac Tissue Constructs With Inotropic Drug Exposure.

Direct Contraction Force Measurements of Engineered Cardiac Tissue Constructs With Inotropic Drug Exposure.

Frontiers in pharmacology (2022-05-21)
Maria Koivisto, Milad Mosallaei, Tarja Toimela, Sampo Tuukkanen, Tuula Heinonen
要旨

Contractility is one of the most crucial functions of the heart because it is directly related to the maintenance of blood perfusion throughout the body. Both increase and decrease in contractility may cause fatal consequences. Therefore, drug discovery would benefit greatly from reliable testing of candidate molecule effects on contractility capacity. In this study, we further developed a dual-axis piezoelectric force sensor together with our human cell-based vascularized cardiac tissue constructs for cardiac contraction force measurements. The capability to detect drug-induced inotropic effects was tested with a set of known positive and negative inotropic compounds of isoprenaline, milrinone, omecamtiv mecarbil, propranolol, or verapamil in different concentrations. Both positive and negative inotropic effects were measurable, showing that our cardiac contraction force measurement system including a piezoelectric cantilever sensor and a human cell-based cardiac tissue constructs has the potential to be used for testing of inotropic drug effects.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
フィブリノーゲン ヒト血漿由来, 50-70% protein (≥80% of protein is clottable)
Sigma-Aldrich
アプロチニン ウシ肺由来, lyophilized powder, 3-8 TIU/mg solid
Sigma-Aldrich
(±)-プロプラノロール 塩酸塩, ≥99% (TLC), powder
Sigma-Aldrich
トロンビン ヒト血漿由来, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)